The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of common stock in Sionna Therapeutics, Inc. as of September 30, 2026.
CB Financial Services, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, reporting net income of $5,327 thousand for the third quarter and total assets of $1,627,963 thousand.
Director David Catzel of Versus Systems Inc. filed a Form 4 on November 9, 2026, disclosing the acquisition of stock options on November 6, 2026, with the issuer listed on NASDAQ:VS.
Aaron Kitlowski, an officer of SITE Centers Corp., filed a Form 144 notice on November 9, 2026 with the SEC proposing the sale of 30,062 shares of common stock through Fidelity Brokerage Services LLC on the NYSE.
Director Aric Spitulnik of Versus Systems Inc. filed a Form 4 on November 9, 2026, disclosing the acquisition of stock options in the company's common stock as of November 6, 2026.
Davion Healthcare Plc filed a Form 6-K with the SEC on November 9, 2026, disclosing that 7,877,590 ordinary shares were registered in the name of Cede & Co. as of November 6, 2026, in response to shareholder enquiries.
GS Finance Corp. filed a Free Writing Prospectus on November 9, 2026, disclosing terms for market-linked, auto-callable structured notes tied to the lowest-performing of CrowdStrike Holdings Inc. and Palo Alto Networks, Inc., with a stated maturity expected on November 29, 2029.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of common stock in Replimune Group Inc as of September 30, 2026.
Coronado Global Resources Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting a net loss of $458,543 thousand for the nine months ended September 30, 2026, alongside a $177,459 thousand asset impairment charge recorded in the period.
Director Anirudh Devgan filed a Form 4 with the SEC on November 9, 2026, disclosing an acquisition of 856 shares of Lam Research Corp common stock on November 6, 2026, at a price of $0 per share.